Microbot Medical (NASDAQ:MBOT) issued its earnings results on Tuesday. The biotechnology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03), Fidelity Earnings reports.
Shares of NASDAQ MBOT opened at $8.36 on Friday. The firm’s 50-day simple moving average is $8.79 and its 200 day simple moving average is $7.97. Microbot Medical has a 12-month low of $4.81 and a 12-month high of $12.20.
Separately, Zacks Investment Research upgraded shares of Microbot Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, January 20th.
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature.
Read More: Derivative
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.